Spero

Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

Retrieved on: 
Tuesday, August 9, 2022
FDA, Spero, HBR, GLOBE, Tebipenem, Pyelonephritis, Patient, Infection, Degenerative disease, Therapy, Tuberculosis verrucosa cutis, Nasdaq, ID, Adult, Pharmaceutical industry

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022 at 4:30 p.m.

Key Points: 
  • CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022 at 4:30 p.m.
  • ET to report its second quarter 2022 financial results and provide an update on its business and pipeline.
  • To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13731565.
  • Spero Therapeuticsis developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.

Spero Therapeutics, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm

Retrieved on: 
Monday, July 25, 2022
NASDAQ, Lists of schools in England, GLOBE, Tebipenem, Review, Workforce, NDA, FDA, Company, Pharmaceutical industry, Spero

LOS ANGELES, July 25, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) investors that a class action filed on behalf of investors. Spero investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Key Points: 
  • LOS ANGELES, July 25, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) investors that a class action filed on behalf of investors.
  • Spero investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

Bronstein, Gewirtz & Grossman, LLC Reminds Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action Deadline and Last Few Hours to Actively Participate

Retrieved on: 
Monday, July 25, 2022
Legal, Professional Services, Tebipenem, Court, Person, Workforce, NDA, NASDAQ, Review, FDA, Lists of schools in England, Complaint, LLC, Security (finance), Spero

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

Key Points: 
  • This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
  • The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and prospects.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)

Retrieved on: 
Friday, July 22, 2022
Class Action Lawsuit, Professional Services, Legal, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Time, Tebipenem, Court, Food, Twitter, Law, Workforce, NDA, HBR, Therapy, New Drug Application, NASDAQ, Urinary tract infection, News, Review, FDA, Company, Defendant, Lists of schools in England, Suite, Pharmaceutical industry, Spero

On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.

Key Points: 
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • If you purchased or otherwise acquired Spero securities during the Class Period, you may move the Court no later than July 25, 2022 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Spero Therapeutics, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm

Retrieved on: 
Thursday, July 21, 2022
NASDAQ, Lists of schools in England, GLOBE, Tebipenem, Review, Workforce, NDA, FDA, Company, Pharmaceutical industry, Spero

LOS ANGELES, July 21, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) investors that a class action filed on behalf of investors. Spero investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.        Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

Key Points: 
  • LOS ANGELES, July 21, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) investors that a class action filed on behalf of investors.
  • Spero investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

SPRO FINAL DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Spero Therapeutics, Inc. Investors With Losses Over $100K to Secure Counsel Before Important July 25 Deadline in Securities Class Action – SPRO

Retrieved on: 
Thursday, July 21, 2022
Titan, Urinary tract infection, GLOBE, Tebipenem, Court, Food and Drug Administration, Twitter, Food, Class, New Drug Application, Workforce, NDA, WHY, Advertising, NASDAQ, THE, Facebook, I-Space (Chinese company), FDA, LinkedIn, Pyelonephritis, Lists of schools in England, Spero, TO, Medical device, Insurance, Tobacco

WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.
  • If you wish to serve as lead plaintiff, you must move the Court no later than July 25, 2022.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Pomerantz Law Firm Announces the Filing of a Class Action Against Spero Therapeutics, Inc. and Certain Officers – SPRO

Retrieved on: 
Monday, July 18, 2022
News, District court, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MDR, Person, SEC Rule 10b-5, LLP, Review, Lists of action films, GLOBE, Securities Exchange Act of 1934, Food, Urinary tract infection, Lists of schools in England, Tebipenem, Complicated, LCM, New Drug Application, HBR, Complaint, Ext, NASDAQ, Infection, Company, NDA, Court, Degenerative disease, Pomerantz, FDA, Treatment, Workforce, Population, Pharmaceutical industry, Renewable energy, Spero, Pyelonephritis

NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO) and certain of its officers.

Key Points: 
  • NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members.

ROSEN, A TOP RANKED LAW FIRM, Encourages Spero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRO

Retrieved on: 
Sunday, July 17, 2022
Titan, Advertising, WHY, Facebook, THE, LinkedIn, Spero, I-Space (Chinese company), GLOBE, Food, Urinary tract infection, Twitter, Lists of schools in England, Pyelonephritis, Tebipenem, New Drug Application, NASDAQ, Class, NDA, Food and Drug Administration, TO, Court, FDA, Workforce, Medical device, Insurance, Tobacco

WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CareDx, Spero, LMP, and Dentsply Sirona and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, July 16, 2022
News, Audit committee, LMP, Spero, Review, Board, Kidney, Company, Government, California superior courts, Population, Medicare, SEC, Dentsply Sirona, Relevant, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Annual report, Food, Income, Complaint, NASDAQ, Physician, Anesthetic, Defendant, Patient, Class Action, Urinary tract infection, Lists of schools in England, Tebipenem, CDNA, Superior, Degenerative disease, COVID-19, XRAY, NDA, Risk, Growth, Plaque, Workforce, Justice, Mission statement, GLOBE, Complicated, New Drug Application, Marketing, Documentation, Infection, Sale, FDA, ASP, Treatment, HBR, Pharmaceutical industry, Animal, Renewable energy, Audit, Medical device, Property management, P.C, Pyelonephritis

Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.

Key Points: 
  • Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.
  • In order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the Class Period.
  • For more information on the Dentsply Sirona class action go to: https://bespc.com/cases/XRAY
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)

Retrieved on: 
Wednesday, July 13, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, New Drug Application, GPM, Lists of schools in England, HBR, News, Therapy, Company, Review, Food, GLOBE, Urinary tract infection, Time, Suite, Defendant, FDA, NDA, Tebipenem, Court, Workforce, NASDAQ, Medical device, Pharmaceutical industry, Spero

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles